Bacterial Conjunctivitis Treatment Currently in Shortage

The shortage is due to a delay with shipping and is anticipated to be available again in October 2018.
The shortage is due to a delay with shipping and is anticipated to be available again in October 2018.

The antibiotic eye drop Azasite (azithromycin ophthalmic solution 1%; Akron Inc.) is currently unavailable due to a delay in shipping of the drug, according to the Food and Drug Administration (FDA). 

Azasite, a macrolide antibiotic, is indicated for use in bacterial conjunctivitis caused by susceptible isolates of the following microogranisms: CDC coryneform group G, Haemophilus influenzae, Staphylococcus aureus, Streptococcus mitis group, and Streptococcus pneumoniae.

Related Articles

The product is anticipated to become available again in October 2018. 

For more information visit FDA.gov.